News | August 11, 2021
Sequent Scientific net profit at Rs 87.30 lakh in Q1FY22
Formulation business grew by 15 per cent in the quarter
Formulation business grew by 15 per cent in the quarter
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The drug is indicated for mild and transient episodes of heart block
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
The company expects revenue growth of 10-15 per cent in the US
India business contributes to a stellar performance
Subscribe To Our Newsletter & Stay Updated
